{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ixazomib+4+mg&page=2", "query": { "intervention": "Ixazomib 4 mg", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 44, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ixazomib+4+mg&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ixazomib+4+mg&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T20:55:26.746Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03323151", "title": "A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mantle-Cell Lymphoma" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PrECOG, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2018-08-13", "completion_date": "2023-09-07", "has_results": true, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-19T20:55:26.746Z", "location_count": 14, "location_summary": "Atlanta, Georgia • Augusta, Georgia • Urbana, Illinois + 11 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03323151" }, { "nct_id": "NCT01912222", "title": "Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Hematologic Malignancies" ], "interventions": [ { "name": "IXAZOMIB", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2013-08", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-06-02", "last_synced_at": "2026-10-19T20:55:26.746Z", "location_count": 4, "location_summary": "Fairway, Kansas • Cleveland, Ohio • Dallas, Texas + 1 more", "locations": [ { "city": "Fairway", "state": "Kansas" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01912222" }, { "nct_id": "NCT02440464", "title": "Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Allogeneic HSCT", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 57, "start_date": "2015-08", "completion_date": "2020-10-01", "has_results": true, "last_update_posted_date": "2023-01-04", "last_synced_at": "2026-10-19T20:55:26.746Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Duarte, California • Tampa, Florida + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02440464" }, { "nct_id": "NCT02312258", "title": "A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 706, "start_date": "2015-04-09", "completion_date": "2022-08-26", "has_results": true, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-19T20:55:26.746Z", "location_count": 23, "location_summary": "Fountain Valley, California • Los Angeles, California • Oceanside, California + 19 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Redlands", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02312258" }, { "nct_id": "NCT02250300", "title": "MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Allogeneic Hematopoietic Stem Cell Transplantation" ], "interventions": [ { "name": "MLN9708 (2.3 mg)", "type": "DRUG" }, { "name": "MLN9708 (4.0 mg)", "type": "DRUG" }, { "name": "MLN9708 (3.0 mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mehdi Hamadani", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2014-11-19", "completion_date": "2020-10-06", "has_results": true, "last_update_posted_date": "2023-03-08", "last_synced_at": "2026-10-19T20:55:26.746Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02250300" }, { "nct_id": "NCT03880123", "title": "Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liposarcoma", "Malignant Peripheral Nerve Sheath Tumors", "Alveolar Soft Part Sarcoma", "Ewing Sarcoma", "Sarcoma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Matthew Ingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": 0, "start_date": "2020-11", "completion_date": "2020-11-24", "has_results": false, "last_update_posted_date": "2020-11-27", "last_synced_at": "2026-10-19T20:55:26.746Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03880123" }, { "nct_id": "NCT03170882", "title": "A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed and/or Refractory Multiple Myeloma" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2017-08-01", "completion_date": "2021-11-26", "has_results": true, "last_update_posted_date": "2022-12-20", "last_synced_at": "2026-10-19T20:55:26.746Z", "location_count": 10, "location_summary": "Fayetteville, Arkansas • Santa Rosa, California • Boca Raton, Florida + 7 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03170882" }, { "nct_id": "NCT01659658", "title": "Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed or Refractory Systemic Light Chain Amyloidosis" ], "interventions": [ { "name": "IXAZOMIB", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 177, "start_date": "2012-12-26", "completion_date": "2022-07-11", "has_results": true, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-10-19T20:55:26.746Z", "location_count": 15, "location_summary": "Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01659658" }, { "nct_id": "NCT01564537", "title": "A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 722, "start_date": "2012-08-01", "completion_date": "2022-02-08", "has_results": true, "last_update_posted_date": "2023-03-10", "last_synced_at": "2026-10-19T20:55:26.746Z", "location_count": 18, "location_summary": "Little Rock, Arkansas • Anaheim, California • Berkeley, California + 15 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Lecanto", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01564537" }, { "nct_id": "NCT02253316", "title": "Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ixazomib", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 236, "start_date": "2015-01-20", "completion_date": "2026-08-31", "has_results": true, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-10-19T20:55:26.746Z", "location_count": 10, "location_summary": "Duarte, California • San Francisco, California • Denver, Colorado + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02253316" } ] }